Shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) have received a consensus broker rating score of 2.00 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company. Sonoma Pharmaceuticals’ rating score has declined by 100% in the last three months as a result of various analysts’ upgrades and downgrades.
Brokerages have set a twelve-month consensus price objective of $8.00 for the company and are forecasting that the company will post ($0.65) EPS for the current quarter, according to Zacks. Zacks has also assigned Sonoma Pharmaceuticals an industry rank of 204 out of 265 based on the ratings given to related companies.
SNOA has been the subject of a number of recent research reports. Benchmark initiated coverage on shares of Sonoma Pharmaceuticals in a report on Thursday, December 28th. They issued a “speculative buy” rating and a $10.00 price objective for the company. Zacks Investment Research downgraded shares of Sonoma Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Finally, Maxim Group set a $7.00 price objective on shares of Sonoma Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 8th.
Sonoma Pharmaceuticals stock traded down $0.17 during midday trading on Friday, reaching $3.77. 52,471 shares of the company’s stock were exchanged, compared to its average volume of 51,950. The company has a quick ratio of 3.83, a current ratio of 4.62 and a debt-to-equity ratio of 0.01. The company has a market cap of $18.26, a P/E ratio of -1.35 and a beta of 1.24. Sonoma Pharmaceuticals has a 52-week low of $3.50 and a 52-week high of $8.25.
Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings data on Wednesday, February 7th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.10). The business had revenue of $4.84 million during the quarter, compared to the consensus estimate of $4.50 million. Sonoma Pharmaceuticals had a negative net margin of 70.46% and a negative return on equity of 70.95%. research analysts forecast that Sonoma Pharmaceuticals will post -2.86 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/03/21/zacks-analysts-set-8-00-target-price-for-sonoma-pharmaceuticals-inc-snoa.html.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.